Global hypomethylation has been linked to disease progression in several cancers, but has not been reported for Diffuse Large B Cell Lymphoma (DLBCL). This study aimed to assess global methylation in DLBCL and describe its prognostic value. Mean LINE1 methylation, a validated surrogate measure for global methylation, was measured in DNA from 67 tumor biopsies. Additionally, cell-free circulating DNA (cfDNA) in plasma samples from 74 patients was tested to assess the feasibility of global hypomethylation as a biomarker in liquid biopsies. LINE1 methylation was assessed using a commercially available kit, based on pyrosequencing of PCR amplified bisulfite-treated DNA. Global hypomethylation was detected in a subset of cases and was associated with poor overall survival in both tumor biopsies (P 5 .001) and cfDNA (P 5 .009). It was the strongest risk factor in multivariate analysis in both biopsies (HR: 10.65, CI: 2.03-55.81, P 5 .005) and cfDNA (HR: 11.87, CI: 2.80-50.20, P 5 .001), outperforming conventional clinical risk factors.
tionally, cell-free circulating DNA (cfDNA) in plasma samples from 74 patients was tested to assess the feasibility of global hypomethylation as a biomarker in liquid biopsies. LINE1 methylation was assessed using a commercially available kit, based on pyrosequencing of PCR amplified bisulfite-treated DNA. Global hypomethylation was detected in a subset of cases and was associated with poor overall survival in both tumor biopsies (P 5 .001) and cfDNA (P 5 .009). It was the strongest risk factor in multivariate analysis in both biopsies (HR: 10.65, CI: 2.03-55.81, P 5 .005) and cfDNA (HR: 11.87, CI: 2.80-50.20, P 5 .001), outperforming conventional clinical risk factors.
Finally, hierarchical cluster analyses were performed for the cfDNA samples using previously published gene-specific methylation data. This analysis shows that global hypomethylation co-occurs with other epigenetic abnormalities, including DAPK1 promoter hypermethylation. In conclusion, we have shown that global hypomethylation is strongly associated with poor survival in DLBCL both when present in tumor biopsy DNA and when detected in plasma cfDNA, and has potential for clinical application as a prognostic biomarker.
| I N T R O D U C T I O N
Lymphoid malignancies are a complex and variable group of diseases.
Diffuse large B cell lymphoma (DLBCL) represents the most common subgroup amongst adults. It is more prevalent over the age of 50, and the 5 year overall survival rate for patients with DLBCL varies between 50% and 85%, depending on disease stage. 1 Epigenetic changes play a major role in both normal B cell maturation and DLBCL development. In normal germinal center B cells, epigenetic instability is vital to the process of developing specific highaffinity immunoglobulins. However, this instability can also contribute to malignant transformation, and epigenetic changes remain a major feature of DLBCL cells. Genes that function as epigenetic regulators are commonly mutated in DLBCL, with less intratumoral heterogeneity than other cancer-driving mutations, suggesting a role in early tumorgenesis. 2 DNA methylation is an epigenetic mark associated with gene silencing, 3 which mainly occurs at cytosine nucleotides when found adjacent to guanine (CpG sites). CpG sites show clustering in specific genomic regions. These clusters of high CpG density are known as CpG islands, and are often found in gene promotor regions. 3 Although the exact mechanism is yet to be defined, there is evidence that methylation provides a "memory" mark of gene silencing, whilst blocking of transcription is carried out by associated histone modifications.
methylation has been validated as a surrogate measure for global DNA methylation. 6 Global hypomethylation is a recognized feature of malignancy, and greater degrees of hypomethylation have been found to be associated with disease progression in several cancers. For example, hypomethylation is more marked in a chronic myeloid leukemia with blast crisis than in the stable phase of the disease. 7 Global hypomethylation is linked to increased metastatic potential and poorer survival in melanoma, and to disease recurrence in proximal colon cancers. 8, 9 Also, supporting this evidence, LINE1 hypermethylation is described as a positive prognostic factor in glioblastoma multiforme.
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Circulating cell-free DNA (cfDNA) offers the possibility for molecular diagnostics in cancer using peripheral blood samples, termed a liquid biopsy. 11 DNA is shed into the blood stream from the tumor site due to cell necrosis. 12 The proportion of plasma DNA originating from the tumor is variable, and influenced by multiple factors, e.g., release of DNA from tumor-associated normal cells, and clearance from the bloodstream. 13 Nonetheless, detection of tumor-associated genetic
and epigenetic changes has been demonstrated in plasma samples in numerous cancers. 13 There are several advantages to this approach, including ability to observe changes through treatment without repeat biopsy, and the ability to test material from all malignant sites (i.e., primary and metastatic sites) with one test. 11, 12 Presence of tumorrelated cfDNA is a prognostic marker, and also a marker of molecular remission, in DLBCL, and can detect relapse before clinically detectable disease by imaging. 11 We hypothesized that global hypomethylation in DLBCL confers a poor prognosis, as described in other malignancies. Finally, we performed hierarchical cluster analyses for the cfDNA samples to investigate associations between global hypomethylation and gene-specific promoter methylation changes, using previously published data for DAPK1, DBC1, miR34A, and miR34B/C in these samples. 14 
| MATERIALS A ND METHODS

| Patients and samples
This retrospective study included a total of 132 patients diagnosed with extra-CNS DLBCL, who were treated at a specialized hematological department in Denmark. Tumor biopsies were available from 67 of the patients and plasma samples from a cohort of 74 patients from a previously published study. 14 Both tumor biopsies and plasma samples were available for nine of the patients. All samples were obtained at the time of diagnosis, prior to initiation of treatment. Data for overall survival (all-cause mortality) was retrieved from a registry database.
Survival data could not be attained for three patients with only plasma samples available. Thirty-five of the tumor biopsies were stored as formalin fixed paraffin embedded (FFPE) tissue samples, and the remaining 32 were fresh frozen.
| Ethics
This 
| Global methylation analysis
LINE1 methylation was assessed using the Therascreen ® LINE1 Pyro ® kit (Qiagen, Hilden, Germany), which is based on pyrosequencing of bisulfite-treated and methylation independent PCR 16 amplified DNA.
PCR was carried out using 40 ng of bisulfite converted DNA, and performed according to the manufacturer's instructions. The PCR product was pyrosequenced using a PyroMark Q24 analyzer (Qiagen), according to the manufacturer's instructions. Results were analyzed using PyroMark Q24 software. LINE1 methylation is analyzed at three different CpG sites. The quality of the results is checked within the software using standard settings. Results were included if the analysis was successful at a minimum of two out of three sites. The mean methylation level across successful sites was used as the final measure of LINE1 methylation.
| Cluster analysis and combined survival analysis of DAPK1 promoter methylation and global hypomethylation
Promoter-specific methylation data was available for the cfDNA samples, from a previously published study. 14 Pyrosequencing of bisulfite treated DNA had been carried out, using specifically designed PCR and sequencing primers for each gene promoter (details available in our previous publication). 14 Here, we report, for the first time, a hierarchical cluster analysis for the cfDNA sample group, including data on promoter hypermethylation of DAPK1, DBC1, miR34A, and miR34B/C, 14 in addition to the global hypomethylation data generated in this study.
The hierarchical cluster analysis was generated using a previously described method. 17 DAPK1 was selected for combined survival analysis with global hypomethylation because it has the greatest impact on survival among these markers. 14 
| Statistical analysis
Global hypomethylation was defined as a LINE1 methylation level more than one standard deviation (SD) below the cohort mean. SPSS version 22 (IBM analytics, USA) was used for statistical analyses. Correlations between OS rates and global methylation status as well as clinical characteristics were estimated using the Kaplan-Meier method with the use of a log-rank test. The clinical characteristics and treatment outcomes were compared according to global methylation status using Students t-tests, Pearson's chi-square tests, or Fisher s exact tests when expected values were below five. For assessment of independent predictors of OS, a multivariate Cox regression hazard model was applied. Any differences were considered statistically significant when the P-value was <.05.
| R E S U LTS
3.1 | Global hypomethylation can be identified in a subset of tumor biopsies and cfDNA samples
The mean LINE1 methylation in the tumor biopsies was 74.3% (SD 5.84). Eight samples had methylation levels greater than one SD below the cohort mean and were thus defined as globally hypomethylated (Figure 1) . Two of the hypomethylated samples were from FFPE biopsies and six from fresh frozen biopsies, and the tissue preservation method did not influence the probability of detecting global hypomethylation (P 5 .102, Fisher s exact test). The mean LINE1 methylation in the cfDNA sample group was 72.0% (SD 3.42). Six samples were greater than one SD below the mean and thus defined as globally hypomethylated (Figure 1 ).
| Global methylation status according to patient characteristics
The baseline clinical characteristics of the DLBCL patients with tumor biopsies available as a function of global methylation status are shown in Supporting Information Table S1 . There was no significant association between methylation status and sex, presence of extra-nodal involvement, disease stage, elevated LDH, IPI score, performance score, age, or rituximab treatment. However, there was a significant association between presence of B symptoms and global hypomethylation (P 5 .017). There was no significant association between methylation status and any of the baseline clinical characteristics of the patients for which cfDNA from plasma was available (Supporting Information   Table S2 ).
| Global hypomethylation is associated with poor overall survival
The five-year survival rate in the normally methylated group was 83.1%, compared with 37.5% in the hypomethylated group when studying the tumor biopsies. Kaplan-Meier analysis showed that survival in the hypomethylated group was significantly poorer (P 5.001) (Figure 2A ). The five-year survival rate in the normally methylated group was 66.2%, compared to 33.3% in the hypomethylated group when studying the cfDNA samples. Kaplan-Meier analysis showed that survival in the hypomethylated group was significantly poorer (P 5 .009) ( Figure 2B ).
| Global hypomethylation in tumor biopsies is an independent prognostic factor
The following baseline clinical characteristics of the patients were not significantly associated with survival: sex, elevated LDH, B symptoms, and age. There was a significant association between survival and the presence of extranodal involvement (P 5 .011), disease stage (P 5 .001), IPI score (P 5 .001), performance score (P 5 .032) clinical response (P < .001), and rituximab treatment (P 5 .044) (Supporting Information 
| Global hypomethylation in cfDNA samples is an independent prognostic factor
There was no significant association between any of the baseline clinical characteristics of the patients and survival. 14 However, for most of the baseline risk factors, including male sex, age above 60 years, extranodal involvement, poor performance score, and high IPI, a trend towards a poor OS was observed as expected. In multivariate analysis global hypomethylation was an independent risk factor for poor survival with a HR of 11.87 (CI: 2.80-50.20, P 5 .001) ( 
| Comparison of global methylation in paired tumor biopsies and cfDNA samples
Of the nine patients for whom both a tumor biopsy and cfDNA were available, none showed global hypomethylation in cfDNA, but two showed global hypomethylation in their corresponding tumor biopsies.
One of these patients had stage II disease while the other had stage IV.
| Global hypomethylation co-occurs with other epigenetic abnormalities in cfDNA
Clustering of samples with both global hypomethylation and other epigenetic abnormalities was observed (Supporting Information Figure S1 ).
These results prompted us to perform a combined survival analysis for global hypomethylation and DAPK1 promoter hypermethylation. The presence of both abnormalities was a highly significant prognostic factor (P < .001) (Supporting Information Figure S2 ), while a moderate, but nonsignificant reduction in survival was observed for patients with either global hypomethylation or DAPK1 hypermethylation. Global hypomethylation without DAPK1 hypermethylation was a rare event, observed in only one patient, who survived more than 5 years after diagnosis.
| DISCUSSION
Global hypomethylation has been shown to be a prognostic factor in chronic myeloid leukemia, melanoma, proximal colon cancers, and glioblastoma multiforme. [7] [8] [9] [10] Our findings clearly demonstrate that this is also the case in DLBCL. Indeed, we have shown, in two separate analyses using samples from different tissues that global hypomethylation is an independent and significant negative predictor of survival with hazard ratios considerably higher than observed for the conventional risk factors and IPI. Male sex conferred a significantly increased risk in both groups, however, with modest HRs compared to global hypomethylation. Male sex has previously been shown to confer poorer prognosis in several largescale studies, although in one of these the survival difference was only seen among younger patients. 18, 19 The biological role of global hypomethylation in malignancy remains unknown. However, methylation of LINE1 and Alu repeats may protect against inappropriate transcription of these repetitive elements, thereby preventing insertional mutagenesis. 20 It is not clear if the observed poor survival associated with LINE1 hypomethylation is a direct result of increased insertional mutagenesis since assessment of this hypothesis was beyond the scope of this study. Another potential biological mechanism is inflammatory stimulation by LINE1 DNA fragments. The presence of LINE1 DNA in cytoplasm has been shown to trigger the cGAS-STRING pathway, leading to interferon expression. 21 It is therefore possible that LINE1 expression has a direct proinflammatory effect. This mechanism may underlie the association between presence of B symptoms and global hypomethylation observed in this study, but this remains conjecture.
Global hypomethylation is not an isolated phenomenon, but is observed in association with gene-specific hypermethylation.
For example, Poage et al. found a significant association between global hypomethylation and selected CpG island hypermethylation in head and neck cancers. 22 Similarly, global hypomethylation and hypermethylation of one studied gene promotor were found to cluster in a study of small intestinal neuroendocrine tumors. 23 We describe clustering of global hypomethylation and promoter hypermethylation of the DAPK1, DBC1 and miR34B/C genes, in cfDNA.
Of these additional epigenetic aberrations we have previously shown DAPK1 hypermethylation to be the strongest prognostic factor. 14 We therefore performed survival analyses for global hypomethylation in combination with DAPK1 hypermethylation. These showed that patients with both abnormalities exhibited very poor survival. DAPK1
hypermethylation was almost always present in patients with global hypomethylation, but it is also likely to confer a moderate increase of risk when present alone. promoter hypermethylation, as this was a rare event in this study.
Our results support the concept of the liquid biopsy, as we have
shown that global hypomethylation in cfDNA is a strong prognostic factor. However, we have also seen that there are potential limitations with this technique, as two patients with tumour biopsy hypomethylation in the overlap group did not have hypomethylation in their cfDNA.
In one of these cases, this may have been due to earlier stage disease (Stage II) as it has been described that more tumor DNA is found in circulation with more advanced stage malignancy. 24 Due to the very small number of patients with both sample types in our study, it is not possible to comment on the sensitivity of cfDNA testing for global hypomethylation. This would require further investigation with a large cohort of patients in whom both tumor biopsy and cfDNA samples were analyzed.
Before these markers can be brought into clinical practice, it is important that our findings are confirmed in independent validation cohorts.
This is particularly important because we used a cut-off for defining hypomethylation which was derived from the cohort itself. Further study of the distribution of global methylation levels in DLBCL would be needed to determine an appropriate fixed cut-off for clinical use.
In conclusion, we have demonstrated that global hypomethylation can be identified in a subset of both tumor biopsy-and cfDNA samples from patients with DLBCL using a commercially available method. It was significantly associated with poorer overall survival in both groups, and was an independent risk factor, conveying a magnitude of risk higher than conventional clinical risk factors. Global hypomethylation was observed to co-occur with other gene-specific epigenetic abnormalities such as DAPK1 hypermethylation, and future studies should aim to elucidate whether these prognostic biomarkers should be used in combination or if one will prevail as a standalone prognostic tool. 
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